Although several tools are available to identify CNAs using read depth (RD) of coverage, 7 they fail to distinguish between large-scale and focal alterations due to inaccurate modeling 8 of the RD signal of cancer genomes. These tools are also affected by RD signal variations, 9 pronounced in low-coverage data, which significantly inflate false detection of change points 10 and inaccurate CNA calling.
INTRODUCTION 1
Copy number variation (CNV) is an essential genetic variation that leads to the change in the 2 number of copies of genomic regions in comparison to the reference genome. CNVs include 3 small-scale (<100 bp) insertions or deletions (indels) and copy number alterations (CNAs).
4
CNA events are 'relative' gain or loss of DNA compared to the reference sample(s) or 5 assembly that are between 1 kb and 3 Mb in size [1] . In cancer, the overwhelming extent of 6 CNA size distribution resulted in their further classification into large-scale (>25% of 7 chromosome arm) or focal events [2, 3] . First, microscopic level large-scale copy number 8 variations (LCVs) concern chromosomal abnormalities that can be cytogenetically detected between several kb to a few Mb in size containing a small number of genes [5] believed to 12 harbor important oncotargets. Therefore, CNV detection methodology needs to be tuned to 13 identify both large-scale and focal events and should include procedures to distinguish them.
14 Both LCVs and focal alterations (FAs) occurring at different genomic length scale and 15 amplitude, hold tremendous value for cancer diagnostics and therapeutics. Naturally, their 16 accurate detection is crucial for gaining insights on their origin and biological context.
17
Numerous computational tools have been developed for CNV detection using next-generation 18 sequencing (NGS) data [6] [7] [8] . These tools are in strong demand as they are central to CNV FAs. Moreover, RD based CNV detection tools are adversely affected by low-coverage data 34 resulted in overdispersion and short-term variations such as wave artifacts [17] [18] [19] . In such 35 scenarios, statistics-based segmentation [9, 14, 20] and CNV calling lead to either in false 36 segmentation or missing the focal alterations. However, low-coverage NGS data is still more 37 efficient than array-based data for CNV analysis [21] .
38
To address these challenges, we developed CNAtra (Copy Number Alteration ( 
Estimation of CNAtra calibration parameters

45
We employ the exponential regression function to model the relationship between the data 46 coverage and CNAtra parameters such as resolution, amplification, and deletion thresholds.
47
We used datasets of high genome coverage (10x-14x) which include 1000 Genomes Project 48 datasets (HG00119, HG01879, HG00096) and A427 cell line. Then, we computed the 49 optimum values of the analysis parameters of the original and subsampled data. Subsampling 50 was performed using Picard (http://broadinstitute.github.io/picard/) and SAMtools [25] .
51
These values were used for fitting the exponential regression models. 
Data availability
63
All the datasets used in this study are publicly available (Supplementary Table 1 performance evaluation of CNAtra. represented as 'sharp' peaks and troughs respectively (Fig. 1b, Fig. 1d; Supplementary Fig. S1 ). We also found that medians of RD signal across segments with the same copy number to define the IBs (Fig. 2b middle panel) 
RESULTS
77
After defining the IBs, we found that RD signal from each IB follows the normal distribution 78 using Q-Q plot and Kolmogorov-Smirnov test with a reasonably good approximation (5% 79 significance level) (Supplementary Fig. S2 ). Therefore, we use each IB as a population of 80 bins for the discovery of statistically significant FAs (Class 1) using the t-test. However, due (Fig. 2b bottom panel) . another copy number state (Supplementary Fig. S3 ). However, low-coverage data suffer from 97 higher variability resulting in false-calling of focal CNAs with the same threshold (Fig. 2c) .
98
Therefore, we define the coverage-based parameters (resolution, amplification and deletion 99 thresholds) to adapt with this overdispersion in low-coverage data (Fig. 2d) . CNAtra is 100 calibrated using several WGS datasets of high coverage. We utilized negative exponential 101 regression for modeling the relation between sequencing coverage and the coverage-based 102 parameters. Our thresholding parameter enables a user to strike a balance between false 103 positives and false negatives. For example, using the same threshold of 0.5N, the 104 subsampling of A427 data to 3.2x coverage yields more false positives compared to the 105 original 10.67x coverage (Fig. 2c top and middle panel) . Increasing the threshold gets rid of 106 these false positives (Fig. 2c bottom panel) . Therefore, the advantage of coverage-based 107 parameter tuning makes the CNAtra results more robust at different data coverage. 
CNAtra detects experimentally validated LCVs and FAs across cell lines
109
We evaluated the ability of CNAtra to detect and distinguish both large-scale and focal events 110 using validated data as 'ground truth' from multiple cancer datasets. For LCVs, CNAtra (Fig. 3b) . In both these Fig. 3c; Supplementary Fig. S4 ). Supplementary Fig. S5b ).
CNAtra confirms the CNV profiles identified by SNP array in CCLE and
140
Taken together, CNAtra detected 89.5% COSMIC and 80% of CCLE calls. LCVs maintaining the inherent CNA features and complexities of the RD signal (Fig. 4a) .
155
We generated simulated CNV profiles using low-coverage (<2x) CHP-212, IMR-32, and Therefore, we compute f-measure to estimate detection accuracy which balances the 183 precision and the recall values. CNAtra showed the highest f-measure value of 87.77% 184 followed by FREEC which showed 56.8% (Fig. 4c) . Next, we plot the ROC (receiver 185 operating characteristic) curve for evaluating the performance of the tools under the 186 assumption that the maximum cumulative focal CNA locus length is 10% of the genome (for 187 estimation of true negatives). The ROC curve clearly shows that CNAtra is superior in 188 detecting focal CNAs in terms of true-positive and false-positive rates (Fig. 4d) Table 4 ). Rest of the tools failed to detect any LCV event. We repeated this procedure to 192 generate three additional simulated CNV profiles using different widths, frequencies, and 193 copy numbers. All the analysis showed similar relative performance between the tools as 194 demonstrative using ROC curves (Supplementary Fig. S6c ; Supplementary Table 4) .
195
In addition, we found that CNAtra is robust in estimating the CN reference regardless of the 196 presence of LCVs. We stated earlier that LCVs could adversely affect local median that in 197 turn can affect the copy number estimation. For example, after spiking the RD signal with 198 LCVs, the global median changes by 3-7% (Fig. 4e) which may lead to the wrong estimation 199 of CN reference. Despite this, CNAtra can correctly estimate the CN reference (Fig. 4e) . We 200 also analysed the computation time of all CNV detection tools (Supplementary Table 5 ). We 
211
We utilized this visual inspection approach to comprehensively understand the advantages 212 and limitations of all tools using cancer datasets.
213
We found that CNAtra is the only tool to comprehensively detect both LCVs and focal 214 alterations ( Fig. 5; Supplementary Fig. S7 and S8) . Moreover, we found that most tools are 215 affected by imperfect segmentation of the large segments. For example, all tools except 216 CNAtra have wrongly attributed the monoallelic 1p deletion in CHP-212 neuroblastoma cells 217 into several segments. Only CLImAT identified this 1p deletion as a single event; however, 218 they fail to correctly determine the right boundary of the segment (Fig. 5) . Additionally, the 219 focal amplification (FA1) inside the monoallelic 1p segmental deletion, which harbors 220 enhancer region based on ENCODE ChromHMM [52] , is detected by CNAtra, CNVnator 221 and AMYCNE (Fig. 5) . Also, 1q segmental amplification (correctly detected by CNAtra and (Fig. 5) .
229
This effect is more evident in the A427 triploid cell line (Fig. 1d) is wrongly identified as a deletion event since the median of the RD signal is matching the 232 3N (black line Fig. 1d A427) and not the correct CN reference (2N) (blue line in Fig. 1d 233 A427). All the tools are affected by overdispersion in low-coverage data which may result in 234 false positives and false negatives as estimated using simulated data. CNAtra circumvents 235 this problem using thresholding parameters; however, the user can apply higher stringency 236 thresholding to curate the CNA data manually.
DISCUSSION
1
Hyperploidy and pervasive genetic alterations are the hallmark of cancer genomes. In the 2 current study, we analyzed several cancer cells with different levels of aneuploidy which 3 showed a complex multimodal distribution due to widespread large-scale and focal CNAs. High-coverage (>15x) WGS datasets are generally used for CNA profiling; however, they are 16 not available for many cancer cell lines. As an alternative solution, the ChIP-seq 'input' NGS 17 reads can be effectively used which are publicly available for many cell lines. These input 18 reads are generated from sonicated chromatin and typically used to normalize and peak
19
calling of the ChIP-seq data. These input data contain the genome-wide reads but they are 20 generally sequenced at low-coverage (<2x). These data can be judiciously utilized to compute 
33
One of the major limitations of the performance evaluation of CNV detection tools is the 34 non-availability of a complete repertoire of 'experimentally validated' cancer CNA profiles.
35
Therefore, we generated realistic simulated data using the available cancer data as input to 36 maintain the signal variability and features of cancer RD signal. Then we introduced CNAs 37 of different length-scales randomly as 'artificial' ground truth. We benchmarked CNAtra 38 against five currently available tools using this simulated data. We established that CNAtra is 39 the only tool to stratify large-scale and focal CNAs which reflect critical biological features.
40
CNAtra beats all other competing tools in higher precision and sensitivity which are 41 corroborated by visual inspection. To sum up, we believe that CNAtra is the ideal approach
42
(guide) to tackle complex and low-coverage cancer datasets. CNAtra has immense potential 43 to add value towards the study of cancer genomes as well as discovery of novel CNAs. 
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